Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 4 |
| List of Tables | 4 | 1 |
| List of Figures | 5 | 1 |
| Introduction | 6 | 1 |
| Global Markets Direct Report Coverage | 6 | 1 |
| Essential Thrombocythemia Overview | 7 | 1 |
| Therapeutics Development | 8 | 1 |
| Pipeline Products for Essential Thrombocythemia Overview | 8 | 1 |
| Essential Thrombocythemia Therapeutics under Development by Companies | 9 | 1 |
| Essential Thrombocythemia Pipeline Products Glance | 10 | 2 |
| Late Stage Products | 10 | 1 |
| Clinical Stage Products | 11 | 1 |
| Essential Thrombocythemia Products under Development by Companies | 12 | 1 |
| Essential Thrombocythemia Companies Involved in Therapeutics Development | 13 | 9 |
| Aop Orphan Pharmaceuticals AG | 13 | 1 |
| F. Hoffmann-La Roche Ltd. | 14 | 1 |
| Galena Biopharma, Inc. | 15 | 1 |
| Gilead Sciences, Inc. | 16 | 1 |
| Incyte Corporation | 17 | 1 |
| Italfarmaco S.p.A. | 18 | 1 |
| MEI Pharma, Inc. | 19 | 1 |
| Novartis AG | 20 | 1 |
| PharmaEssentia Corporation | 21 | 1 |
| Essential Thrombocythemia Therapeutics Assessment | 22 | 9 |
| Assessment by Monotherapy Products | 22 | 1 |
| Assessment by Target | 23 | 2 |
| Assessment by Mechanism of Action | 25 | 2 |
| Assessment by Route of Administration | 27 | 2 |
| Assessment by Molecule Type | 29 | 2 |
| Drug Profiles | 31 | 42 |
| anagrelide hydrochloride CR Drug Profile | 31 | 3 |
| anagrelide hydrochloride PR Drug Profile | 34 | 1 |
| givinostat Drug Profile | 35 | 2 |
| momelotinib dihydrochloride Drug Profile | 37 | 5 |
| peginterferon alfa-2a Drug Profile | 42 | 1 |
| pracinostat Drug Profile | 43 | 5 |
| ropeginterferon alfa-2b Drug Profile | 48 | 2 |
| ruxolitinib phosphate Drug Profile | 50 | 13 |
| sonidegib phosphate Drug Profile | 63 | 4 |
| vismodegib Drug Profile | 67 | 6 |
| Essential Thrombocythemia Dormant Projects | 73 | 1 |
| Essential Thrombocythemia Discontinued Products | 74 | 1 |
| Essential Thrombocythemia Product Development Milestones | 75 | 6 |
| Featured News &Press Releases | 75 | 1 |
| Sep 12, 2016: Galena Biopharma Expands GALE-401 Intellectual Property Protection with Patent Issuance in Japan | 75 | 1 |
| Jun 13, 2016: Galena Biopharma Presents GALE-401 Combined Safety Data at the European Hematology Association 21st Congress | 75 | 1 |
| Nov 18, 2014: Galena Biopharma Completes Enrollment In GALE-401 (Anagrelide Controlled Release) Phase 2 Clinical Trial | 76 | 1 |
| Feb 13, 2013: Novartis's Myelofibrosis Drug Jakavi Turned Down By NICE In Draft Guidance | 77 | 1 |
| May 31, 2011: YM BioSciences Announces Orphan Drug Designation For JAK1/JAK2 Inhibitor CYT387 In Europe | 78 | 1 |
| Dec 06, 2010: Incyte Presents Positive Phase II Trial Results Of INCB18424 In Advanced Polycythemia Vera And Essential Thrombocythemia At ASH Annual Meeting | 78 | 2 |
| May 28, 2009: Incyte Provides Update on Special Protocol Assessment for INCB18424 As A New Treatment for Myelofibrosis | 80 | 1 |
| Appendix | 81 | 2 |
| Methodology | 81 | 1 |
| Coverage | 81 | 1 |
| Secondary Research | 81 | 1 |
| Primary Research | 81 | 1 |
| Expert Panel Validation | 81 | 1 |
| Contact Us | 81 | 1 |
| Disclaimer | 82 | 1 |